Podcast: Play in new window | Download
Subscribe: Spotify | Email | RSS | More
In this Diving Deep episode, Dr. Robert Pearl and Jeremy Corr examine two very different healthcare debates that share a common problem: when medicine lacks good evidence and aligned incentives, patients and doctors are left with bad choices.
The conversation begins with experimental peptides, a fast-growing topic on social media and in wellness circles. Dr. Pearl reviews the FDA’s ongoing debate over whether six experimental peptides should be made available to licensed compounding pharmacies. Supporters argue that Americans are already buying these substances through the gray market, often from overseas suppliers, and that regulated access would be safer. Critics argue that expanded access would encourage far more people to use products whose benefits, risks, purity and long-term safety remain uncertain.
For Pearl, both sides are partly right, which is why a simple yes or no is the wrong answer.
Saying no would not eliminate demand. It would leave many Americans buying peptides online without reliable quality control. Saying yes without conditions would create the impression of FDA approval without the scientific evidence normally required to prove safety and efficacy. Instead, Pearl argues for a third path: pair regulated access with federally coordinated research, safety reporting and controlled studies so patients, doctors and regulators can learn whether these peptides actually work and whether they are safe.
The second half of the episode turns to primary care, a specialty Pearl says is in serious trouble.
Primary care physicians are overburdened, under-resourced and underpaid compared with specialists. They face growing patient panels, administrative demands, declining autonomy and less interest from medical students entering the field.
Pearl acknowledges that primary care leaders are right to ask for more respect, more support and better compensation. But he argues that payers are unlikely to invest substantially more unless primary care can demonstrate better outcomes and lower total costs. That has not happened consistently under traditional fee-for-service or pay-for-performance programs, which reward isolated steps in care rather than overall clinical impact.
The solution is capitation. Under this model, primary care doctors would receive a prospective payment to care for a defined population rather than being paid for each visit or service. If chronic diseases are controlled, emergency department use falls and complications decline, both patients and clinicians benefit. But capitation also requires doctors to accept financial risk, organize into larger groups, adopt common clinical standards, coordinate care and empower effective physician leaders.
The episode closes with a call for national primary care societies to lead. Pearl says they can help doctors form groups, negotiate capitated contracts, purchase stop-loss protection, implement generative AI, build clinical infrastructure and spread best practices from early demonstration programs.
Across both topics, Pearl returns to the same point. Whether the issue is experimental peptides or the future of primary care, patients need evidence, doctors need accountability and the system needs incentives that reward better health.
For more, tune into this month’s episode and check out the link below.
Helpful links:
- The Best FDA Decision On Peptide Authorization Isn’t Yes Or No (Forbes)
- Monthly Musings on American Healthcare (RobertPearlMD.com)
* * *
Dr. Robert Pearl is the author of ChatGPT, MD: How AI-Empowered Patients & Doctors Can Take Back Control of American Medicine.
Fixing Healthcare is a co-production of Dr. Robert Pearl and Jeremy Corr. Subscribe to the show via Apple, Spotify or wherever you find podcasts. Join the conversation or suggest a guest by following the show on X and LinkedIn.